Lipigon completes oversubscribed new share issue


Lipigon Pharmaceuticals has successfully closed a new share issue of nearly € 1,6 million. The capital raised will primarily be used to take the most advanced programme of the company towards clinical trials.


“We met a great deal of interest in this transaction, which ended up oversubscribed. We are pleased that our current shareholders continue to support us and are also happy to welcome our new investors.”, says Dr. Stefan K Nilsson, co-founder and CEO at Lipigon Pharmaceuticals.


Read more below.



Press release new share issue final
.pdf
Download PDF • 158KB